Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425370 | 1.00 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1KCNJ1HRH3RET | |
| SCHEMBL2424920 | 0.87 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HRH3 | |
| SCHEMBL2424922 | 0.87 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HRH3 | |
| SCHEMBL13885207 | 0.87 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1KCNJ1HRH3 | |
| SCHEMBL2424112 | 0.86 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HRH3RET | |
| SCHEMBL2424108 | 0.86 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HRH3RET | |
| SCHEMBL1116633 | 0.85 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HRH3 | |
| SCHEMBL1116635 | 0.85 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HRH3 | |
| SCHEMBL12294278 | 0.83 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1RET | |
| SCHEMBL13450349 | 0.83 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | HSP90AA1 1888/4885HSP90AB1 1352/4885KCNJ1 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.